sidenav header background
sidenav background

《中国药物经济学评价指南》 (2008-2015)

发布日期:2017-07-05 09:24:00 来源:北京大学国家发展研究院

《中国药物经济学评价指南》 (2008-2015)

Chinese Pharmacoeconomics (PE) Guidelines

药物经济学评价是为了全面科学的了解药品使用的真正价值。药物经济学评价方法已在很多国家被越来越广泛的应用于医疗保险报销目录和价格的管理与制定。药物经济学指南可用于规范希望进入药品报销目录的药物经济学实验的报告;药物经济学实验的设计和实施;和决策者对药物经济学报告的评估。经过课题组全体研究人员和国内外咨询专家的共同努力,最终形成了中国药物经济学评价指南。希望本指南的使用,能够加强中国药物经济学的学科发展,提高医药卫生资源的配置效率,促进中国医药卫生事业的发展。

The main function of PE guidelines is to evaluate the true economic values of medical technologies. The PE analytical tools have been used increasingly in decision-making progress for the financing and management of medical products in the drug policy formulary and clinical decisions. Pharmacoeconomic guidelines can be used as a standard for the PE study of a product to be included in the drug formulary; a guide for designing and implementing a study; or a template for PE reports by decision makers. With the efforts of the PKU research group, together with the domestic and international consultants, the Chinese Pharmacoeconomic Guidelines have been documented. The Guidelines are intended to help facilitate the development of Pharmacoeconomic research, and to improve the efficiency of healthcare resources allocation in China.